Washington, Aug 23 (AP) Pfizer is spending more than USD 2 billion in cash to buy a drugmaker focused on cancer treatments.

Pfizer will pay USD 18.50 for each share of Trillium Therapeutics Inc., or more than double the stock's 60-day weighted average price.

Also Read | Afghanistan Crisis: Germany Top Military Commander Eberhard Zorn Says About 5,000 People Waiting to Evacuate at Kabul Airport.

Trillium has no products on the market. Its potential treatments include biologics that aim to prime a patient's immune system to detect and destroy cancer cells.

Its two lead candidates are in early-stage testing and focus on hematology. That includes blood, bone marrow and lymph node cancers like leukemia or lymphoma.

Also Read | Thailand May Delay Planned Reopening of Pattaya to Vaccinated Travellers on September 1 Due to Insufficient Inoculations and Spike in COVID-19 Cases.

The deal announced Monday will need approval from Trillium shareholders.

Pfizer, based in New York, invested USD 25 million in Trillium last September, and one of the leaders of Pfizer's cancer research was named to Trillium's scientific advisory board.

Pfizer Inc. said last month that its COVID-19 vaccine brought in nearly half of its second-quarter revenue, but cancer treatments also have been a growing sales generator for the company.

Cancer treatments brought in USD 10.9 billion in revenue last year, and Pfizer's oncology products include treatments for breast, colorectal, blood and lung cancers.

Pfizer's stock climbed almost 3 per cent at the opening bell. Shares of Trillium, based in Cambridge, Massachusetts, nearly tripled to USD 17.73. (AP)

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)